These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26414102)

  • 1. Lyme borreliosis: reviewing potential vaccines, clinical aspects and health economics.
    Šmit R; Postma MJ
    Expert Rev Vaccines; 2015; 14(12):1549-61. PubMed ID: 26414102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against tick-transmitted Lyme disease in dogs vaccinated with a multiantigenic vaccine.
    Straubinger RK; Dharma Rao T; Davidson E; Summers BA; Jacobson RH; Frey AB
    Vaccine; 2001 Oct; 20(1-2):181-93. PubMed ID: 11567763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination against Lyme disease: past, present, and future.
    Embers ME; Narasimhan S
    Front Cell Infect Microbiol; 2013; 3():6. PubMed ID: 23407755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tick-Tattoo: DNA Vaccination Against
    Klouwens MJ; Trentelman JJA; Wagemakers A; Ersoz JI; Bins AD; Hovius JW
    Front Immunol; 2021; 12():615011. PubMed ID: 33717102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination to Prevent Lyme Disease: A Movement Towards Anti-Tick Approaches.
    Johnson EE; Hart TM; Fikrig E
    J Infect Dis; 2024 Aug; 230(Supplement_1):S82-S86. PubMed ID: 39140718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lyme disease: uphill struggle.
    Abbott A
    Nature; 2006 Feb; 439(7076):524-5. PubMed ID: 16452949
    [No Abstract]   [Full Text] [Related]  

  • 7. Demonstration of the ability of a canine Lyme vaccine to reduce the incidence of histological synovial lesions following experimentally-induced canine Lyme borreliosis.
    Grosenbaugh DA; Rissi DR; Krimer PM
    Vet Immunol Immunopathol; 2016 Nov; 180():29-33. PubMed ID: 27692092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
    Wressnigg N; Pöllabauer EM; Aichinger G; Portsmouth D; Löw-Baselli A; Fritsch S; Livey I; Crowe BA; Schwendinger M; Brühl P; Pilz A; Dvorak T; Singer J; Firth C; Luft B; Schmitt B; Zeitlinger M; Müller M; Kollaritsch H; Paulke-Korinek M; Esen M; Kremsner PG; Ehrlich HJ; Barrett PN
    Lancet Infect Dis; 2013 Aug; 13(8):680-9. PubMed ID: 23665341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Need for a New Lyme Disease Vaccine.
    Plotkin SA
    N Engl J Med; 2016 Sep; 375(10):911-3. PubMed ID: 27602662
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative analysis of antibody responses to outer surface protein (Osp)A and OspC in dogs vaccinated with Lyme disease vaccines.
    Camire AC; Hatke AL; King VL; Millership J; Ritter DM; Sobell N; Weber A; Marconi RT
    Vet J; 2021 Jul; 273():105676. PubMed ID: 34148599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: Implications for vaccine development.
    Izac JR; Oliver LD; Earnhart CG; Marconi RT
    Vaccine; 2017 May; 35(24):3178-3185. PubMed ID: 28479174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lyme disease vaccination: safety first.
    Stricker RB; Johnson L
    Lancet Infect Dis; 2014 Jan; 14(1):12. PubMed ID: 24355028
    [No Abstract]   [Full Text] [Related]  

  • 13. Lyme disease vaccination: are we ready to try again?
    Lantos PM
    Lancet Infect Dis; 2013 Aug; 13(8):643-4. PubMed ID: 23665340
    [No Abstract]   [Full Text] [Related]  

  • 14. Lyme disease vaccination: safety first - authors' reply.
    Barrett PN; Crowe BA; Wressnigg N; Portsmouth D; Aichinger G
    Lancet Infect Dis; 2014 Jan; 14(1):12-13. PubMed ID: 24355029
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
    Eschner AK; Mugnai K
    Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lyme disease vaccination: safety first - author's reply.
    Lantos PM
    Lancet Infect Dis; 2014 Jan; 14(1):13. PubMed ID: 24355030
    [No Abstract]   [Full Text] [Related]  

  • 17. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.
    Scheckelhoff MR; Telford SR; Hu LT
    Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reservoir targeted vaccine against Borrelia burgdorferi: a new strategy to prevent Lyme disease transmission.
    Richer LM; Brisson D; Melo R; Ostfeld RS; Zeidner N; Gomes-Solecki M
    J Infect Dis; 2014 Jun; 209(12):1972-80. PubMed ID: 24523510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking pathogen transmission at the source: reservoir targeted OspA-based vaccines against Borrelia burgdorferi.
    Gomes-Solecki M
    Front Cell Infect Microbiol; 2014; 4():136. PubMed ID: 25309883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis.
    Steere AC; Drouin EE; Glickstein LJ
    Clin Infect Dis; 2011 Feb; 52 Suppl 3(Suppl 3):s259-65. PubMed ID: 21217173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.